Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Calculators
Our Services
My Account
Do not call
En
Learn about Rodec Pharma Limited’s Draft Red Herring Prospectus filing, business operations, financial context, and the proposed utilisation of funds as outlined in public disclosures.
Rodec Pharma Limited has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) as part of its plan to raise capital through an initial public offering. The DRHP outlines the company’s pharmaceutical manufacturing operations, product portfolio, regulatory framework, financial performance, and the broad structure of the proposed public issue. This page presents an educational overview of the DRHP-stage developments, highlighting the company’s background, IPO objectives, financial context, and the next milestones in the IPO journey, based solely on publicly available disclosures.
The DRHP provides an overview of the proposed IPO and sets out the company’s financials, governance framework, and business outlook.
Rodec Pharma Limited filed its Draft Red Herring Prospectus with SEBI in January 2026, marking the formal initiation of its IPO process. The filing is currently under regulatory review, following which SEBI observations and approvals will determine subsequent stages, including the filing of the Red Herring Prospectus (RHP) and announcement of issue dates.
The equity shares are proposed to be listed on recognised stock exchanges in India, subject to regulatory approvals.
As per the DRHP, the proposed IPO is expected to comprise the following components:
| Particulars | Details |
|---|---|
Issue Type |
Offer for Sale (OFS) of Equity Shares |
Issue Size |
To be finalised in RHP |
Face Value |
To be disclosed |
Fresh Issue |
Not applicable |
Offer for Sale |
Sale of equity shares by existing shareholders |
Proposed Listing |
NSE and BSE |
Price Band |
To be announced in RHP |
These details reflect indicative disclosures available at the DRHP stage and are subject to change based on SEBI observations and final approvals.
Rodec Pharma Limited operates in the veterinary healthcare sector and is engaged in the manufacturing and distribution of veterinary pharmaceutical products and animal nutrition solutions. The company offers a range of veterinary formulations and feed supplements catering to livestock, poultry, and companion animals across multiple therapeutic and nutritional categories.
The company operates manufacturing facilities equipped with pharmaceutical production technology, quality control systems, and regulatory compliance infrastructure applicable to veterinary healthcare products. Its operations span product development, manufacturing, packaging, quality testing, and distribution within the veterinary segment.
Rodec Pharma maintains relationships with distributors, dealers, and veterinary practitioners across India, enabling broad market access. The company operates under applicable veterinary pharmaceutical and feed regulatory approvals, including manufacturing licences, product registrations, and compliance with prescribed regulatory and quality standards.
Its business model is supported by manufacturing capabilities, a diversified veterinary product portfolio, regulatory compliance, and participation in India’s animal healthcare and nutrition market, driven by rising livestock productivity needs and increasing focus on animal health management.
As per the DRHP, the proposed IPO of Rodec Pharma Limited comprises an Offer for Sale (OFS) by existing shareholders. Since the issue does not include a fresh issue component, the company will not receive any proceeds from the IPO.
The key proposed objectives include:
Partial exit by existing shareholders
Listing of equity shares on recognised stock exchanges
Creation of liquidity and a public market for the shares
Broader public participation in the company’s equity
These aspects reflect the purpose of the OFS, which is to facilitate shareholder monetisation while enabling Rodec Pharma Limited’s listing and market visibility.
The DRHP provides an overview of Rodec Pharma Limited’s financial performance, reflecting its operational scale and pharmaceutical manufacturing activities.
| Fiscal Year / Period | Revenue (₹ Cr) | EBITDA (₹ Cr) | PAT (₹ Cr) |
|---|---|---|---|
FY24 |
89.61 |
Not publicly disclosed in summary |
11.04 |
FY25 |
108.19 |
Not publicly disclosed in summary |
18.26 |
H1 FY26 |
62.7 |
Not publicly disclosed in summary |
9.7 |
*Detailed year-wise financial statements, including audited figures, are available in the DRHP and should be referred to for complete financial information.
The table below summarises the current status of the IPO process based on publicly available disclosures:
| Milestone / Stage | Date (or Status) | Details |
|---|---|---|
DRHP filed with SEBI |
January 2026 |
Draft Red Herring Prospectus filed for public disclosure |
SEBI observations |
Awaited |
Subject to regulatory review |
SEBI approval for IPO |
Awaited |
Approval expected post-DRHP review |
Red Herring Prospectus (RHP) |
Awaited |
Final prospectus to be filed post approval |
IPO Opening Date |
To be announced |
Final dates awaited |
IPO Closing Date |
To be announced |
Dependent on official notification |
Allotment of Shares |
To be announced |
Post IPO closure |
Credit to Demat Accounts |
To be announced |
After allotment finalisation |
Listing on NSE/BSE |
To be announced |
Post allotment and listing formalities |
Note: Investors should refer to official filings for final IPO dates to learn more about Rodec Pharma Limited IPO listing details and price, and listing timelines.
Keep yourself updated : Check Upcoming IPO
This content is for informational purposes only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Sources
LiveMint — IPO News and Updates, https://www.livemint.com/market/ipo
Economic Times — IPO News: Latest IPO News, Upcoming IPO, https://economictimes.indiatimes.com/markets/ipo
Financial Express — IPO News, https://www.financialexpress.com/market/ipo-news/
NDTV Profit — IPOs, https://www.ndtvprofit.com/ipos
Business Today — IPO Corner: Latest IPO News & Analysis, https://www.businesstoday.in/markets/ipo-corner
Rodec Pharma Limited filed its Draft Red Herring Prospectus with SEBI on 11 January 2026. This Rodec Pharma IPO filed with SEBI marks the formal regulatory step in the IPO process, with further updates expected after SEBI observations are received.
The Rodec Pharma IPO is currently at the DRHP review stage. SEBI observations on the Rodec Pharma Limited IPO DRHP filing are awaited. Once SEBI provides its observations and the company addresses them, the Red Herring Prospectus (RHP) will be filed with the Registrar of Companies, following which the IPO opening date will be announced.
As per the DRHP, the Rodec Pharma IPO is proposed as an Offer for Sale (OFS) by existing shareholders. The IPO does not include a fresh issue of equity shares, and therefore the company will not receive any proceeds from the public offer. The exact issue size, price band, and final structure will be disclosed in the Red Herring Prospectus (RHP) after SEBI observations and approvals. The proceeds from the Offer for Sale will be received by the selling shareholders and not by the company.
Subject to regulatory approvals, Rodec Pharma Limited plans to list its equity shares on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE), providing investors access to Rodec Pharma Limited equity shares on both major Indian stock exchanges.
Rodec Pharma Limited is a pharmaceutical manufacturing company focused on producing and marketing pharmaceutical formulations across multiple therapeutic categories. The business focus is on tablets, capsules, syrups, injectables, and other dosage forms for domestic and potentially international markets. Details about specific pre-IPO investors, strategic backers, or notable shareholders will be available in the DRHP and subsequent offer documents.
As per the Rodec Pharma Limited IPO DRHP, the company has reported its recent financial performance including revenue from operations, EBITDA, profit after tax (PAT), total assets, and net worth for the last financial years. Exact figures for revenue, EBITDA, margins, profit, and balance sheet metrics should be taken from the official DRHP and audited financial statements, which provide a complete view of Rodec Pharma’s financial position and performance.
.jpeg)
250 Views
| 1min read
Posted on 19 Dec
Academy 
.jpeg "image not found"){kind=small}
